Viatris to buy Pacira for $1.65 billion in cash
Viatris said it will acquire Pacira BioSciences for $1.65 billion, or $36.50 a share, in cash. The company expects the deal to close by year-end and to have a minimal impact on gross leverage.
By Mackenzie Tatananni Viatris is expanding its footprint in the non-opioid painkillers market with the acquisition of Pacira BioSciences, joining other drugmakers in a race to address a critical gap in public health. 20. Viatris said it plans to fund the Pacira acquisition primarily through excess cash, with the remainder coming from short-term borrowings. It expects the deal to have a minimal impact on its gross leverage ratio.
The transaction is slated to close by year's end. The transaction centers on Pacira's portfolio of non-opioid pain medications, notably Exparel and Zilretta, two extended-release therapies approved for specific post-surgical and joint conditions. Viatris CEO Scott Smith expects these patented drugs will be "synergistic" with an anti-inflammation drug it is developing. He noted that the acquisition could position the company as "a leader in non-opioid pain management therapies" amid surging demand from patients and healthcare providers alike.
30 on Thursday. 7%. S. history, many drugmakers are exploring non-addictive alternatives.
However, these medications have proven difficult to bring to market, as development programs historically have been fraught with high failure rates. As different patients experience and express chronic pain differently, broad-brush clinical trials often struggle to demonstrate consistent efficacy. Moreover, scientists still lack a complete understanding of the precise biological and mechanistic underpinnings of pain. A major milestone occurred in January of last year, when Vertex Pharmaceuticals won approval for its Journavx pill, which was formerly one of the most-watched pipeline candidates in the biotech sector.
The drug targets sodium channels in the peripheral nervous system to block pain signals before they reach the brain, becoming the first drug to be approved in this new class of pain-management medicines. The world's largest drugmaker, Eli Lilly, has continued its push into the market despite past setbacks, most recently acquiring 4E Therapeutics in June to snap up its pipeline of oral MNK inhibitors, which can stop the generation of pain signals. Viatris was founded in 2020 through the merger of Pfizer's Upjohn division and generic drug manufacturer Mylan. Its most notable products today include brand-name EpiPens and the cholesterol-regulating medication Lipitor.
The company also manufactures standard generic meloxicam tablets to treat chronic inflammation. Its novel fast-acting formulation is currently under review, with regulators poised to decide by Dec. 27 whether or not to approve it. S.
Pharmaceuticals exchange-traded fund. The approval of fast-acting meloxicam could provide yet another catalyst. com This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires October 08, 2026 12:01 ET (16:01 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.